Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 444,740
  • Shares Outstanding, K 43,860
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,670 K
  • 36-Month Beta 2.15
  • Price/Sales 92.85
  • Price/Cash Flow N/A
  • Price/Book 4.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.36 +22.01%
on 12/20/17
10.50 -2.86%
on 01/19/18
+1.79 (+21.28%)
since 12/19/17
3-Month
7.63 +33.68%
on 12/06/17
10.50 -2.86%
on 01/19/18
+2.02 (+24.69%)
since 10/19/17
52-Week
1.46 +598.63%
on 01/23/17
10.50 -2.86%
on 01/19/18
+8.48 (+493.02%)
since 01/19/17

Most Recent Stories

More News
Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis

Study allows continued access to long-term treatment with seladelpar in support of the phase 3 registration program

CBAY : 10.20 (+0.59%)
CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Sujal...

JPM : 113.01 (-0.22%)
CBAY : 10.20 (+0.59%)
CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Paul...

CBAY : 10.20 (+0.59%)
Factors of Influence in 2018, Key Indicators and Opportunity within MGM Resorts International, Celanese, Motorola Solutions, Sunrun, CymaBay Therapeutics, and Arrow Electronics -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MGM Resorts International...

MGM : 36.35 (+0.78%)
CE : 112.96 (+1.74%)
MSI : 97.80 (+0.31%)
ARW : 86.94 (+3.34%)
CBAY : 10.20 (+0.59%)
RUN : 5.94 (+0.34%)
CymaBay Therapeutics to Present at Three Investor Conferences

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management...

CBAY : 10.20 (+0.59%)
CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial...

CBAY : 10.20 (+0.59%)
CymaBay Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / CymaBay Therapeutics, Inc. (NASDAQ: CBAY) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 PM Eastern...

CBAY : 10.20 (+0.59%)
CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will...

CBAY : 10.20 (+0.59%)
CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the...

CBAY : 10.20 (+0.59%)
CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that...

CBAY : 10.20 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 10.72
1st Resistance Point 10.46
Last Price 10.20
1st Support Level 9.98
2nd Support Level 9.76

See More

52-Week High 10.50
Last Price 10.20
Fibonacci 61.8% 7.05
Fibonacci 50% 5.98
Fibonacci 38.2% 4.91
52-Week Low 1.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.